Adaptive Biotechnologies (ADPT) Cash & Equivalents (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Cash & Equivalents data on file, last reported at $77.6 million in Q1 2026.

• Quarterly Cash & Equivalents rose 53.18% year-over-year to $77.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.6 million (up 53.18% YoY) and the FY2025 annual result came in at $70.5 million, up 47.11% from the prior year.
• Cash & Equivalents advanced to $77.6 million in Q1 2026 per ADPT's latest filing, from $70.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $217.6 million in Q3 2022, with the low at $38.1 million in Q3 2024.
• Average Cash & Equivalents over 5 years is $80.6 million, with a median of $71.2 million recorded in 2024.
• Year-over-year, Cash & Equivalents jumped 77.74% in 2022 and plunged 59.22% in 2023.
• Adaptive Biotechnologies' Cash & Equivalents stood at $90.0 million in 2022, then declined by 27.73% to $65.1 million in 2023, then fell by 26.35% to $47.9 million in 2024, then jumped by 47.11% to $70.5 million in 2025, then advanced by 10.05% to $77.6 million in 2026.
• Business Quant data shows ADPT's Cash & Equivalents at $77.6 million in Q1 2026, $70.5 million in Q4 2025, and $55.0 million in Q3 2025.